|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Avanir_Pharmaceuticals
Bristol-Myers_Squibb's_medical_imaging_business
|
|
gptkbp:awards
|
Best Employer Awards
Pharma Innovation Awards
Corporate_Social_Responsibility_Awards
Global_Health_&_Pharma_Awards
Japan's_Best_Workplaces
|
|
gptkbp:CEO
|
gptkb:Taro_Iwamoto
|
|
gptkbp:founded
|
1964
|
|
gptkbp:founder
|
gptkb:Akihiko_Otsuka
|
|
gptkbp:globalPresence
|
Over 20 countries
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Otsuka Holdings Co., Ltd.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market
|
¥3.5 trillion (2021)
|
|
gptkbp:notableEvent
|
gptkb:Otsuka's_Medical_Devices
gptkb:Otsuka's_Nutraceuticals
gptkb:Rexulti
Vraylar
Abilify MyCite
|
|
gptkbp:numberOfEmployees
|
approximately 47,000
|
|
gptkbp:partnerships
|
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
gptkb:Lundbeck
|
|
gptkbp:philanthropy
|
gptkb:Otsuka_Foundation
|
|
gptkbp:products
|
gptkb:Samsca
Abilify
Seroquel
Nuedexta
|
|
gptkbp:researchFocus
|
Oncology
Infectious Diseases
Cardiovascular Diseases
Metabolic Disorders
Central_Nervous_System_Disorders
|
|
gptkbp:revenue
|
¥1.5 trillion (2020)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Otsuka_Canada_Pharmaceutical_Inc.
gptkb:Otsuka_Pharmaceutical_Co.,_Ltd.
gptkb:Otsuka_America_Pharmaceutical,_Inc.
|
|
gptkbp:sustainabilityInitiatives
|
Sustainable Development Goals (SDGs)
Carbon Neutrality Goals
Waste Reduction Programs
Water Conservation Efforts
Environmental_Management_System
|
|
gptkbp:type
|
Public
|
|
gptkbp:website
|
www.otsuka.com
|